Observational Study of Asparaginase and Liver Damage
This study is looking at how your genes might affect whether you develop liver damage (hepatotoxicity) when treated with asparaginase for acute lymphoblastic leukemia (ALL). Researchers will collect a saliva sample from you to look for specific genetic markers. The goal is to see if these markers can help doctors predict who might have liver problems with asparaginase. This could help doctors better manage treatment for people with ALL. You may be able to join if you are newly diagnosed with ALL and receiving asparaginase, or if you received asparaginase between 2012 and 2017 and are a current patient at the University of Southern...
- Study design
- This is an observational study planning to enroll 500 participants. It is not a treatment study but rather looks at existing medical information and collected samples.
- What's involved
- You would provide a saliva sample, typically during a regular clinical visit. For those already treated, samples will be collected during a regular clinical visit after consent.
- Compensation
- Not stated in the trial record.
- Follow-up
- Liver damage will be measured for up to 6 months after treatment with asparaginase.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
At a glance
Conditions
NCT03568266
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Los Angeles General Medical Center
Los Angeles, Californiastudy coordinator listed
Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Houda Alachkar, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Southern California
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Hepatotoxicity following treatment with asparaginaseUp to 6 months
Hepatotoxicity per Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and defined as \> or = grade 3 of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT), or \> or = grade 3 bilirubin elevation.